|Spark Therapeutics Inc -- Germany Stock|| |
EUR 44.26 0.63 1.40%
Co-Founder and CTO
Dr. J. Fraser Wright Ph.D. is CoFounder and Chief Technology Officer of Spark Therapeutics Inc. From July 2013 until he joined Spark Dr. Wright served as our Chief Technology Advisor. Dr. Wright established and had been the director of the Clinical Vector Core Laboratory at CHOP from 2004 to January 2015. Dr. Wright also was a Professor at the Perelman School of Medicine at the University of Pennsylvania. Dr. Wright previously served as Director of Development and Clinical Manufacturing at Avigen Inc. from 1999 to 2004 and as scientist with Sanofi Pasteur and as scholar investigator with the Canadian blood services
Age: 56 Founder Since 2015 Ph.D
Wright received his B.S. and Ph.D. in biochemistry from the University of Toronto.
The company has return on total asset (ROA)
of (24.8) %
which means that it has lost $24.8 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (49.14) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 1.3 M in total debt with debt to equity ratio (D/E) of 0.2 which may suggest the company is not taking enough advantage from borrowing. Spark Therapeutics Inc has Current Ratio of 15.47 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Spark Therapeutics Inc (272) is traded on Frankfurt Stock Exchange in Germany. and employs 27 people.